|View printer-friendly version|
Wellcome Trust-Funded Projects Expand Partnerships with Charles River’s Global Discovery Services Business
“We are delighted Antabio, Pcovery, and the
As part of the agreements, Charles River’s Discovery Business will provide a comprehensive suite of in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics (DMPK), and medicinal chemistry services, which are outlined below:
British Columbia Cancer Agency, Charles River will begin a new project providing chemistry/computer-aided drug design (CADD), biochemical and cell assays, and in vitro and in vivo DMPK studies to improve radiotherapy treatments for cancer.
- For Antabio, Charles River will begin a new project developing a novel drug for infections in cystic fibrosis patients with project management, CADD, and medicinal and synthetic chemistry input. Charles River will also continue providing Antabio with medicinal and synthetic chemistry, CADD, and in vitro and in vivo DMPK services to develop drug candidates that inhibit antibiotic resistance.
- For Pcovery, Charles River will continue providing CADD and medicinal and synthetic chemistry support to develop antifungal treatments with the potential to destroy otherwise drug-resistant fungi.
For each project, the Charles River Discovery team worked closely with
its respective partners, providing scientific support and insight into
the development of the grant applications, and the generation and
delivery of scientific presentations to the
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
For more information visit www.criver.com
Charles River Laboratories International, Inc.
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
Executive Director, Public Relations